



Hepatocellular Carcinoma: From Pathophysiology to Therapeutic Approaches Treatment

Guest Editor:

Dr. Wasim A. Dar

Transplant Surgeon, Hartford
Healthcare and UCONN Health,
263 Farmington Ave, Farmington,
CT 06030, USA

Deadline for manuscript
submissions:

30 November 2025

Message from the Guest Editor

Dear Colleagues,

Hepatocellular carcinoma represents a rapidly growing cause of worldwide cancer morbidity and mortality. Potential curative treatments for HCC have been limited to transplantation and surgical resection. However, emerging clinical, translational, and basic science data have shown promising results in identifying new treatment modalities such as neoadjuvant and adjuvant immunotherapy. In addition, new locoregional techniques such as histotripsy also open up new possibilities in the management of HCC for patients with tumors not amenable to resection or liver transplantation. This Special Issue seeks to highlight the advances in the basic science of HCC and in clinical treatment, and we welcome submissions that offer novel insights into HCC's etiology, progression, and potential treatment.

Dr. Wasim A. Dar
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)